Boehringer Ingelheim Metabolism Partnership

Posted August 2015

• Boehringer Ingelheim and Circuit Therapeutics will investigate neuronal circuits involved in obesity to develop new ways of treating metabolic diseases
• With this cooperation Boehringer Ingelheim underscores its leadership in cardiometabolic research and development

Ingelheim, Germany and Menlo Park, CA, USA, 12 August 2015 - Boehringer Ingelheim and Circuit Therapeutics today announced a second collaboration using Circuit’s proprietary optogenetics technology platform. This new three-year collaboration will focus on investigating metabolic disorders with the aim of developing novel medicines to improve the treatment of obesity and associated diseases. The prior collaboration between the two companies focused on the discovery of new treatments for neuropsychiatric disorders.

Boehringer Ingelheim is a leader in cardiometabolic disease research and development and has ambitious strategic goals in diabetes and metabolism. The new collaboration is intended to broaden Boehringer Ingelheim’s pipeline in this area. Eating disorders are among the major contributing factors to the development of overweight and obesity which are major risk factors for type 2 diabetes, heart disease, high blood pressure, and other health problems.

Circuit’s optogenetics technology will be used to identify targets in central nervous circuits relevant for obesity, and central and peripheral circuits relevant for coordinating food intake. These insights will provide both companies with a better understanding of the mechanisms involved in obesity. It will also enable the prioritization of novel targets with a potential for therapeutic intervention superior to current standard of care in obesity. The ongoing collaboration between the companies in the area of neuropsychiatry has already yielded first targets for symptoms of anhedonia (the inability to feel and experience pleasure) relevant to a number of psychiatric disorders which will be investigated further by Boehringer Ingelheim.

“Boehringer Ingelheim is excited about the potential of the optogenetics technology platform developed by Circuit and wants to carry on the success already achieved in the area of neurology into the area of metabolism,” said Dr Michel Pairet, Senior Corporate Vice President of Research and Non-clinical Development at Boehringer Ingelheim. He added, “This new technology may enable us to unravel the neurological circuits responsible for metabolic disorders down to individual neurons which could lead to the identification of new targets and subsequently new treatments in line with our corporate vision of improving patients’ lives.”

“We are excited to extend our partnership with Boehringer Ingelheim and utilize Circuit’s technological capabilities to advance drug discovery in yet another therapeutic area. The success of our first collaboration is founded in Boehringer Ingelheim’s unique partnering approach and its outstanding internal drug discovery capabilities. Together we aspire to establish a foundation for the development of transformational drugs to impact patients’ lives,” said Fred Moll, Chairman of Circuit Therapeutics.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information please visit www.boehringer-ingelheim.com

About Circuit Therapeutics

Circuit Therapeutics is the world leader in optogenetics—a transformational technology that gives researchers and clinicians the ability to control neural activity with light. Optogenetics enables unparalleled specificity and temporal control of neural circuits, and has allowed Circuit to create an unrivaled platform for discovery and validation of novel drug targets. Founded by Karl Deisseroth, Rob Malenka, Scott Delp, Thomas Sudhof, Anatol Kreitzer, and Karoly Nikolich, Circuit Therapeutics is based in Menlo Park, California.

For more information, please visit www.circuittx.com, or contact JD Vance at jdvance@circuittx.com.

Boehringer Ingelheim US (for US media enquiries)
Susan Holz
Director, Public Relations - Oncology & Immunology
Tel. 203-798-4265
susan.holz@boehringer-ingelheim.com

Contact Circuit Therapeutics
JD Vance
Director of Business Operations and Development
1505 O’Brien Drive, Menlo Park, CA 94025
O: 650-543-1415
jdvance@circuittx.com